Neoadjuvant combination cytotoxic chemotherapy with dual HER2-targeted therapy (trastuzumab and pertuzumab, HP) is the standard of care for stage II/III HER2-positive breast cancer; yielding high pathologic complete response (pCR) rates but with associated toxicity which can be serious. This evidence concerns the gene ERBB2 and breast cancer.